TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.
Animals
Carboxypeptidase B2
/ genetics
Disease Models, Animal
Factor VIII
/ genetics
Female
Genetic Predisposition to Disease
/ genetics
Hemarthrosis
/ complications
Hemophilia A
/ complications
Male
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Knockout
Transcriptome
Vascular Remodeling
/ physiology
Angiogenesis
Coagulation
Hematology
Rheumatology
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
03 10 2019
03 10 2019
Historique:
received:
25
03
2019
accepted:
23
08
2019
pubmed:
30
8
2019
medline:
21
10
2020
entrez:
30
8
2019
Statut:
epublish
Résumé
Excessive vascular remodeling is characteristic of hemophilic arthropathy (HA) and may contribute to joint bleeding and the progression of HA. Mechanisms for pathological vascular remodeling after hemophilic joint bleeding are unknown. In hemophilia, activation of thrombin-activatable fibrinolysis inhibitor (TAFI) is impaired, which contributes to joint bleeding and may also underlie the aberrant vascular remodeling. Here, hemophilia A (factor VIII-deficient; FVIII-deficient) mice or TAFI-deficient mice with transient (antibody-induced) hemophilia A were used to determine the role of FVIII and TAFI in vascular remodeling after joint bleeding. Excessive vascular remodeling and vessel enlargement persisted in FVIII-deficient and TAFI-deficient mice, but not in transient hemophilia WT mice, after similar joint bleeding. TAFI-overexpression in FVIII-deficient mice prevented abnormal vessel enlargement and vascular leakage. Age-related vascular changes were observed with FVIII or TAFI deficiency and correlated positively with bleeding severity after injury, supporting increased vascularity as a major contributor to joint bleeding. Antibody-mediated inhibition of uPA also prevented abnormal vascular remodeling, suggesting that TAFI's protective effects include inhibition of uPA-mediated plasminogen activation. In conclusion, the functional TAFI deficiency in hemophilia drives maladaptive vascular remodeling in the joints after bleeding. These mechanistic insights allow targeted development of potentially new strategies to normalize vascularity and control rebleeding in HA.
Identifiants
pubmed: 31465300
pii: 128379
doi: 10.1172/jci.insight.128379
pmc: PMC6795396
doi:
pii:
Substances chimiques
F8 protein, human
839MOZ74GK
Factor VIII
9001-27-8
Carboxypeptidase B2
EC 3.4.17.20
Cpb2 protein, mouse
EC 3.4.17.20
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL142975
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL104165
Pays : United States
Organisme : NIA NIH HHS
ID : R37 AG059418
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130678
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG056144
Pays : United States
Références
Semin Hematol. 2016 Jan;53(1):10-9
pubmed: 26805902
Nat Med. 2003 Mar;9(3):331-7
pubmed: 12579195
Haemophilia. 2011 Jan;17(1):112-7
pubmed: 21070482
Int J Hematol. 2017 Dec;106(6):787-793
pubmed: 28815418
Ann Rheum Dis. 2000 Apr;59(4):315-8
pubmed: 10733483
Cardiovasc Intervent Radiol. 2017 Feb;40(2):216-222
pubmed: 27882429
Blood. 2005 Apr 1;105(7):2654-7
pubmed: 15613551
Blood. 2011 Feb 24;117(8):2484-93
pubmed: 21163925
Haemophilia. 2013 Jan;19(1):e1-47
pubmed: 22776238
N Engl J Med. 2007 Aug 9;357(6):535-44
pubmed: 17687129
Haemophilia. 2009 May;15(3):802-10
pubmed: 19444976
Haemophilia. 2009 May;15(3):665-75
pubmed: 19432921
J Thromb Haemost. 2008 Jan;6(1):132-8
pubmed: 17922808
Thromb Res. 2014 Mar;133(3):390-5
pubmed: 24252538
Thromb Haemost. 2018 Jun;118(6):1036-1047
pubmed: 29847841
Haemophilia. 2004 Oct;10 Suppl 4:152-6
pubmed: 15479389
Blood. 1996 Nov 1;88(9):3446-50
pubmed: 8896409
Thromb Res. 2012 Mar;129(3):314-9
pubmed: 22113149
Haemophilia. 2012 May;18(3):369-74
pubmed: 22032268
J Clin Invest. 2011 Sep;121(9):3517-27
pubmed: 21804193
Haemophilia. 2006 Nov;12(6):654-62
pubmed: 17083517
Lung. 2012 Apr;190(2):189-98
pubmed: 22037793
Mol Immunol. 2008 Oct;45(16):4080-3
pubmed: 18706698
J Thromb Haemost. 2008 Nov;6(11):1892-9
pubmed: 18752573
Adv Exp Med Biol. 2008;632:61-9
pubmed: 19025114
J Thromb Haemost. 2004 Jan;2(1):111-8
pubmed: 14717974
Blood. 2015 Mar 26;125(13):2038-44
pubmed: 25712992
Lancet. 1997 Mar 15;349(9054):766-8
pubmed: 9074576
Semin Arthritis Rheum. 1992 Jun;21(6):400-14
pubmed: 1626286
Arthritis Rheum. 2009 Oct;60(10):2902-12
pubmed: 19790060
Thromb Haemost. 1998 Nov;80(5):829-35
pubmed: 9843179
Clin Exp Metastasis. 2017 Feb;34(2):155-169
pubmed: 28124276
J Biol Chem. 1998 Jan 23;273(4):2127-35
pubmed: 9442053
J Clin Invest. 2002 Jan;109(1):101-10
pubmed: 11781355
J Thromb Haemost. 2003 Oct;1(10):2087-96
pubmed: 14521589
Arthritis Res Ther. 2015 Mar 13;17:58
pubmed: 25889955
Am J Hematol. 2015 Nov;90(11):1027-35
pubmed: 26257191
Haemophilia. 2012 May;18(3):e316-22
pubmed: 21933309
J Biol Chem. 1996 Jul 12;271(28):16603-8
pubmed: 8663147
BMC Cancer. 2016 May 24;16:328
pubmed: 27221823
J Arthroplasty. 2017 Nov;32(11):3379-3384
pubmed: 28662956
Blood. 2018 Oct 11;132(15):1593-1603
pubmed: 30026184
Semin Hematol. 2013 Apr;50(2):175-84
pubmed: 23956467
J Biol Chem. 2006 Jun 9;281(23):15878-83
pubmed: 16595693
J Biol Chem. 1991 Nov 15;266(32):21833-8
pubmed: 1939207
J Immunol. 2018 Feb 1;200(3):957-965
pubmed: 29282305
Ann Rheum Dis. 2012 Apr;71(4):575-81
pubmed: 22084394
Methods Mol Biol. 2014;1130:149-164
pubmed: 24482171
J Biol Chem. 2003 Dec 19;278(51):51059-67
pubmed: 14525995
Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1363-70
pubmed: 20431069
J Thromb Haemost. 2003 Dec;1(12):2510-5
pubmed: 14675085
Haemophilia. 2008 Jul;14(4):804-9
pubmed: 18422608
Br J Radiol. 2016 Aug;89(1064):20151064
pubmed: 27327402
Pathol Res Pract. 2002;198(5):317-25
pubmed: 12092767
Blood. 2011 Mar 17;117(11):3190-8
pubmed: 21217077
BMC Hematol. 2015 Feb 14;15:4
pubmed: 25692030
Haemophilia. 2012 Sep;18(5):729-37
pubmed: 22639833
Thromb Haemost. 2016 Mar;115(3):551-61
pubmed: 26466980
J Thromb Haemost. 2009 Mar;7(3):453-9
pubmed: 19087221
Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2157-62
pubmed: 17673703
Blood. 2004 Oct 1;104(7):2060-4
pubmed: 15172967
Arthritis Rheumatol. 2014 Jan;66(1):101-106
pubmed: 24449579
Circulation. 1996 Apr 1;93(7):1328-30
pubmed: 8641019
Thromb Haemost. 2001 Oct;86(4):1035-9
pubmed: 11686321
J Biol Chem. 1995 Jun 16;270(24):14477-84
pubmed: 7782309
Genomics. 1992 Oct;14(2):549-50
pubmed: 1427879
Microcirculation. 2016 Jul;23(5):373-8
pubmed: 26833634
Blood. 2002 Aug 1;100(3):912-6
pubmed: 12130502
J Biol Chem. 2008 Nov 21;283(47):32506-15
pubmed: 18799467
J Biol Chem. 1998 Oct 16;273(42):27176-81
pubmed: 9765237
Cardiovasc Intervent Radiol. 2013 Aug;36(4):964-9
pubmed: 23150120
Blood Coagul Fibrinolysis. 2007 Jun;18(4):365-70
pubmed: 17473579
Front Biosci. 2003 Jan 01;8:d1-8
pubmed: 12456318
Haemophilia. 2015 Jul;21(4):530-7
pubmed: 25623830
Arterioscler Thromb Vasc Biol. 2013 Apr;33(4):769-76
pubmed: 23393392